Equities
Health CareHealth Care Providers
  • Price (USD)9.70
  • Today's Change-0.11 / -1.12%
  • Shares traded5.72m
  • 1 Year change-39.18%
  • Beta0.9054
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy1
Outperform5
Hold21
Sell0
Strong Sell0

Share price forecast in USD

The 20 analysts offering 12 month price targets for Teladoc Health Inc have a median target of 10.00, with a high estimate of 14.00 and a low estimate of 8.00. The median estimate represents a 3.09% increase from the last price of 9.70.
High44.3%14.00
Med3.1%10.00
Low-17.5%8.00

Earnings history & estimates in USD

On Oct 30, 2024, Teladoc Health Inc reported 3rd quarter 2024 losses of -0.19 per share. This result exceeded the -0.28 consensus loss of the 21 analysts covering the company and exceeded last year's 3rd quarter results by 45.71%.
The next earnings announcement is expected on Feb 18, 2025.
Average growth rate-236.19%
Teladoc Health Inc reported annual 2023 losses of -1.34 per share on Feb 20, 2024.
Average growth rate-784.96%
More ▼

Revenue history & estimates in USD

Teladoc Health, Inc. had 3rd quarter 2024 revenues of 640.51m. This bettered the 631.16m consensus of the 23 analysts covering the company. This was 1.79% above the prior year's 3rd quarter results.
Average growth rate-0.75%
Teladoc Health, Inc. had revenues for the full year 2023 of 2.60bn. This was 8.13% above the prior year's results.
Average growth rate+52.51%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.